Formation Bio launches $600M fund to advance drug candidates through clinical development

Formation Bio has launched a $600M Drug Development Accelerator Fund that will invest in individual drug programs rather than standalone biotech companies, licensing assets into newly formed asset-centric "NewCos." Each NewCo gets funding through key clinical milestones plus access to Formation Bio's developers, AI systems, and infrastructure. The fund targets drugs 2-4 years from clinical readout, citing over $300 billion in drug sales facing patent expiration over the next decade. The author argues discovery output has doubled in a decade while approvals stayed flat, making development the bottleneck. LPs include research foundations, academic institutions, philanthropies, and hospitals.

✨ AI summary of the linked source — not editorial content.

Explore the topic

• Launch